While the target population in this NMA is different from the one considered by Nuhoho et al., findings in terms of GLP-1 RAs relative efficacy and ranking are consistent between the two studies, indicating that once-daily oral semaglutide is an efficacious add-on therapy for a broad population with T2D, including people with advanced disease
TIMER analysis revealed elevated PD-L1 expression in multiple malignancies
Cost and Accessibility With a manufacturer copay card, you could pay as little as $25 for Zepbound if you have a commercial insurance plan that covers the medication
Prednisolone, DMARDs, or NSAIDs, were not allowed during this study period
This study was small and has not been replicated
The Road Ahead The clinical trial pipeline for GLP-1 agonists and addiction is growing